Examining immune cells in children with ADHD
Official title: Immunoprofilling of Peripheral Blood Mononuclear Cells in Children With Attention Deficit/Hyperactivity Disorder
Run by First Affiliated Hospital of Zhejiang University · NCT06109337 · Data updated 2026-11-12
This study looks at the immune cells in children with ADHD to see how they differ from kids without ADHD and how these differences might relate to their symptoms and brain function.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 6 Years to 12 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | First Affiliated Hospital of Zhejiang University Academic / other |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Status | Recruiting |
| Started | December 4, 2023 |
| Main results expected | May 2027 |
| Study ends | December 2027 |
| Registry record updated | April 1, 2025 |
| Trial ID | NCT06109337 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are children diagnosed with ADHD who have an IQ of 70 or above.
✕Probably not a fit
Patients with schizophrenia, mood disorders, autism, or significant physical and nervous system abnormalities may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to investigate the immune cell landscape of peripheral blood mononuclear cells in children diagnosed with Attention Deficit/Hyperactivity Disorder (ADHD) compared to typically developing controls. It will analyze differences in immune cell subpopulations, protein expression, and signaling pathways using advanced mass spectrometry flow cytometry technology. Additionally, the study will correlate immune function with cognitive assessments and brain imaging results to better understand the relationship between immune profiles and ADHD symptoms.
Why it matters
Potential benefit: If successful, this study could provide insights into the immune mechanisms underlying ADHD, potentially leading to new therapeutic strategies.
How similar studies have gone: While the approach of examining immune profiles in ADHD is relatively novel, similar studies in other conditions have shown promising results.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Clinical diagnosis of ADHD; Children with an IQ≥70; Both parents are Han; Agree to take venous blood with informed consent; Exclusion Criteria: Schizophrenia, mood disorder, autism, mental retardation; Obvious physical and nervous system abnormalities;
Where it's running
-
Fu Guanghui
Hangzhou, Zhejiang, China Recruiting
Study contacts
- Principal investigator: Hu Guanghui, doctor — Department of Psychiatry, the First Affiliated Hospital, Zhejiang University School of Medicine
- Study coordinator: Hu Shaohua, doctor
- Email: dorhushaohua@zju.edu.cn
- Phone: 13957162903
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Biomarkers that predict medication-related side effects in children with ADHD
This study tests whether combined brain, cognitive, and metabolite markers can predict side effects from methylphenidate in kids with ADHD.
-
Group CBT vs. Activity Group for Adults with ADHD
This trial tests whether group cognitive behavioral therapy helps adults with ADHD more than a structured activity group.
-
Central Executive Training and Behavioral Parent Training for Young Children with ADHD
This study tests Central Executive Training (CET) alone and CET combined with Behavioral Parent Training (BPT) to help young children with ADHD.
-
Peanuts and stress: does eating peanuts affect heart health markers in people under high stress
This study tests whether adding roasted peanuts to the diet can improve immune and cardiovascular risk markers in adults who report high chronic stress.
-
Immunomodulatory effects of Spirulina Blue Protein capsules in healthy adults
This study tests whether Spirulina Blue Protein capsules can modulate immune function in healthy adults over 12 weeks, compared with a placebo.
-
Solriamfetol for ADHD in teens: see if it helps with focus
This phase 3 study tests solriamfetol versus placebo in adolescents with ADHD to see if the medication improves symptoms over 6 weeks.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.